Four quick questions. One recommendation.
By treatment area
Formulated to work with light — not just alongside it. Young Goose collab. EWG Green. Made in USA.
About the research on this page. The studies cited here investigate photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in PBM research — not Mito Red Light devices. The wavelengths in our panels were chosen because the peer-reviewed PBM literature supports them. Evidence levels and study counts reflect the broader research base, not studies of our products. See the full methodology note at the bottom of this page.
Princeton-trained molecular biologist specializing in metabolism and cellular energy systems. Dr. Cowan personally reviewed this page for scientific accuracy, citation integrity, and protocol recommendations. Last reviewed: May 3, 2026.
Transcranial photobiomodulation (tPBM) — the application of near-infrared light to the skull and underlying brain tissue — is an emerging field with a growing body of preclinical and clinical evidence supporting effects on neurological function, cognitive performance, and neuroprotection. Unlike visible red light, near-infrared wavelengths (800–1100 nm) penetrate the scalp, skull, and meninges to reach the cerebral cortex. Cytochrome c oxidase in neurons is the primary chromophore, and photon absorption increases mitochondrial ATP production, reduces neuroinflammation, and stimulates neuroprotective signaling pathways including BDNF and NGF upregulation.
Preclinical evidence from traumatic brain injury (TBI), stroke, and neurodegeneration models is extensive and mechanistically compelling. Human clinical trials, though earlier in development than musculoskeletal applications, demonstrate measurable effects on cognitive function, mood, and cerebral blood flow. Pilot RCTs in TBI survivors show improvements in cognitive speed, memory, and PTSD symptom scores. Studies in healthy adults show enhanced executive function, working memory, and reaction time following single sessions of tPBM at 1064 nm or 810 nm. The prefrontal cortex appears particularly responsive, likely due to its high metabolic demand and proximity to the skull surface.
Emerging clinical applications include major depressive disorder, PTSD, mild cognitive impairment (MCI), Alzheimer's disease, and Parkinson's disease. While most human trials remain in Phase I/II stages with small sample sizes, the mechanistic rationale is strong — mitochondrial dysfunction is increasingly recognized as a core pathophysiology in neurodegenerative diseases, and PBM's ability to restore mitochondrial function non-invasively positions it as a potentially transformative neuroprotective intervention. Larger multi-center RCTs are now underway.
Near-infrared light at 800–1100 nm penetrates the skull and is absorbed by cytochrome c oxidase in neurons, restoring mitochondrial membrane potential and increasing ATP synthesis. This rescues metabolically compromised neurons from apoptosis and reduces neuroinflammatory signaling (NF-κB, TNF-α in microglia). PBM also increases cerebral blood flow via nitric oxide-mediated vasodilation and upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), supporting synaptic plasticity and neuroprotection.
Studies in this category commonly demonstrate:
A curated selection from 350++ indexed studies.
Gonzalez-Lima et al. found single-session tPBM at 1064 nm to right prefrontal cortex significantly improved working memory and executive function performance vs. sham. Established foundational human evidence for cognitive enhancement with transcranial NIR.
View on PubMed →Naeser et al. found 18 sessions of tPBM produced significant improvements in neuropsychological tests of memory, attention, and executive function in chronic TBI patients. Improvements were maintained at 1–2 month follow-up.
View on PubMed →fMRI study found single-session tPBM significantly increased cerebral blood flow in prefrontal cortex regions vs. sham. Effect correlated with improved cognitive task performance. Provided neuroimaging evidence for tPBM's vascular effects.
View on PubMed →Daily tPBM for 4 weeks significantly reduced amyloid-beta plaque burden (−30%) and tau phosphorylation in cortex and hippocampus vs. untreated controls. Cognitive performance on Morris water maze also improved. Supports neuroprotective hypothesis.
View on PubMed →Schiffer et al. found significant reductions in depression scores (HAM-D −58%) and anxiety in MDD patients receiving forehead tPBM vs. sham. Effect size was large. Small sample size but rigorous design provided early evidence for tPBM in mood disorders.
View on PubMed →Comprehensive review of 36 studies found consistent evidence for tPBM improving cognitive performance in healthy adults and clinical populations. Prefrontal cortex application at 1064 nm most studied. Safety across all studies: no adverse events. Called for standardized protocols and larger RCTs.
View on PubMed →Based on analysis of 350++ peer-reviewed studies:
| Parameter | Typical Range | Notes |
|---|---|---|
| Wavelength | 810 nm; 1064 nm (transcranial) | 1064 nm has superior skull penetration depth (~2.5 cm). 810 nm more commonly available. Both show cognitive effects in RCTs. |
| Dose (fluence) | 10–20 J/cm² at scalp | Cortical dose estimated at 1–5% of scalp dose due to skull attenuation. Higher scalp doses needed for deeper penetration. |
| Application site | Prefrontal cortex (forehead); temporal/parietal | Prefrontal cortex (Fp1/Fp2 EEG coordinates) most studied. Temporal placement studied for memory; parietal for attention. |
| Session duration | 8–18 minutes per session | Single sessions show acute cognitive benefits. Repeated sessions (8–18 over 4–6 weeks) needed for therapeutic effects in clinical populations. |
| Treatment course | 8–18 sessions over 4–9 weeks | Majority of clinical trials use 2–3 sessions/week for 4–9 weeks. TBI studies show persistent effects at 1–2 month follow-up. |
| Study populations | Healthy adults + TBI + MDD + MCI | Broadest evidence in healthy adults for cognitive enhancement. Clinical evidence in TBI and depression most advanced toward RCT phase. |
Yes — near-infrared light at 810–1064 nm penetrates biological tissue significantly better than visible wavelengths. Monte Carlo light transport modeling and ex vivo skull studies confirm that approximately 1–5% of applied near-infrared irradiance reaches the cerebral cortex through the scalp and skull. While this is a small fraction, neuronal mitochondria are highly sensitive to photon energy, and this cortical dose is sufficient to produce measurable metabolic changes. Studies using 1064 nm demonstrate deeper penetration than 810 nm due to reduced hemoglobin absorption.
Human RCTs have found single-session tPBM at 1064 nm to the prefrontal cortex improves working memory, executive function, reaction time, and attentional performance in healthy adults. Effect sizes are moderate (d=0.4–0.8). In chronic TBI patients, multi-session tPBM improved neuropsychological test scores for memory and attention. These effects are thought to involve enhanced prefrontal cortex metabolic activity and cerebral blood flow.
Preclinical evidence is compelling: animal models show reductions in amyloid-beta plaques, tau phosphorylation, and cognitive decline with repeated tPBM. Human trials are in early stages (Phase I/II), with a few small open-label studies showing safety and preliminary cognitive benefits in mild cognitive impairment (MCI). Larger multi-center RCTs are currently underway. This is a rapidly developing research area, not yet at the level of established clinical guidelines.
Small but rigorous pilot RCTs have reported significant reductions in depression scores (BDI, HAM-D, MADRS) following 8 sessions of forehead tPBM compared to sham. Effect sizes have been large in these early trials, though sample sizes are small (n=10–25). Proposed mechanisms include enhanced prefrontal cortex metabolism, reduced neuroinflammation, and increased serotonin synthesis. Larger confirmatory trials are needed before clinical recommendations can be made.
Safety data across more than 30 published human tPBM studies is reassuring: no serious adverse events have been reported. Mild, transient headache has been noted in a small number of subjects. Standard contraindications include active brain tumors, photosensitizing medications, and skin conditions over the treatment area. The power densities used in tPBM (10–250 mW/cm² at the scalp) are well below tissue damage thresholds established in laser safety standards.
In order of current evidence strength: (1) Cognitive enhancement in healthy adults — multiple crossover RCTs; (2) Traumatic brain injury — pilot RCTs with consistent positive results; (3) Major depressive disorder — small sham-controlled RCTs; (4) Mild cognitive impairment — open-label pilot studies; (5) Alzheimer's disease — compelling preclinical data, early human trials; (6) Parkinson's disease — preclinical evidence, very early human studies. All clinical applications should be considered experimental until confirmed by larger Phase III trials.
All — studies in this category from the PBM research database.
Search all 10,068+ studies across all categories: Open the Full Evidence Explorer →
The published research indexed and referenced on this page studies photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in those studies — not Mito Red Light devices specifically. The wavelengths used across our panels were chosen because the peer-reviewed PBM literature supports them: this is where published evidence is deepest, where dosing parameters have been characterized in human studies, and where clinical guidelines (such as WALT for inflammation and pain) exist. Mito Red Light has not funded or conducted registered clinical trials on our specific devices, and the study counts referenced here reflect the broader PBM research base — not studies of our products.
Evidence levels follow GRADE methodology. Study counts reflect peer-reviewed photobiomodulation research drawn from major scientific literature databases, peer-reviewed journals, and other published research repositories. PBM response varies meaningfully by person, tissue, condition, dose, wavelength, and session timing; outcomes reported in the published literature may not be replicable for every user. Mito Red Light devices are not intended to diagnose, treat, cure, or prevent any disease. If you have a medical condition or are under a physician’s care, please consult your healthcare provider before beginning any photobiomodulation regimen.
